Since the earliest and best-studied action of PCSK9 is its ability to bind to the hepatic LDLR and thereby increase plasma concentrations of atherogenic LDLc, strategies to eliminate PCSK9 have long been an attractive approach to treating hypercholesterolaemia. Here, PCSK9 is linked to Hypercholesterolemia.